Study important as more people using expensive and unregulated CBD supplements that have not been monitored for effectiveness.
Affect of psychosis
The Parkinson’s study, set to begin early next year, is the first large-scale trial which will aim to provide preliminary evidence for the potential benefits and safety of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.
Paula Scurfield, 71, from Beckenham, London, was diagnosed with Parkinson’s in 2014 after developing a very slight tremor on one side of her body. To treat the symptoms of slowness of movement, stiffness and rigidity in muscles and fatigue, she was given the drug Levodopa.
The three-and-a-half-year project is part of the Parkinson’s Virtual Biotech, led by Parkinson’s UK, which is plugging the funding gap in drug development and fast-tracking the projects with the greatest scientific potential to transform the lives of people with Parkinson’s.
“If successful, this trial could result in people with Parkinson’s being able to access a regulated medicine, rather than reverting to expensive and unregulated supplements that haven’t been monitored for their effectiveness.”